Melphalan
Number of HSCT 71 1997-2000 ; Median age, y range ; 8.2 0.2 -19.6 ; Sex male ; 46 64% ; Malignant disease 34 48% ; ALL CR 1 and CR 1 12 17% ; AML CR 1 and CR 1 7 10% ; CML CP ; and MDS 4 6% ; Solid tumor lymphoma 11 15% ; Genetic disorder 37 50% ; Immunodeficiency metabolic disease 25 35% ; Refractory anemias 12 17% ; Autograft 16 23% ; Allograft 55 77% ; Median CD34 cell dose kg recipient 4.0 Donor female ; recipient male ; 15 21% ; Donor CMV - ; recipient CMV - ; 58 80% ; Busulfan 14-20 mg kg ; 53 73% ; Cyclophosphamide 120-200 mg kg ; 42 58% ; TBI 6-14 Gy ; 9 13% ; 6 8% ; Thiotepa 300-900 mg m2 ; 11 15% ; Melphalan 140-180 mg m2 ; Mylotarg 7.5 mg kg ; 0 0% ; Elevated liver enzymes at HSCT 12 17 % ; Multiple HSCT 13 18.
Middot; melphalan is a cancer antineoplastic ; medication.
References 1. 2. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992; 79: 1817-1822. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997; 336: 1202-1207. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloid light-chain ; amyloidosis: survival and responses in 25 patients. Blood. 1998; 91: 3662-3670. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002; 99: 4276-4282. Goodman H, Wechalekar A, Lachmann H, Bradwell A, Hawkins P. Clonal diseaes response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy [abstract]. Haematologica The Hematology Journal. 2005; 90: 201. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis. ASH Annual Meeting Abstracts. 2004; 104: 755. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL primary ; amyloidosis who are ineligible for stem cell transplantation. Blood. 2004; 103: 2936-2938. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004; 103: 20-32. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003; 10: 257-261. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated AL ; amyloidosis. Clin Lymphoma. 2003; 3: 241-246. Dispenzieri A, Lacy MQ, Geyer SM, et al. Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited. ASH Annual Meeting Abstracts. 2004; 104: 4920. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediatedose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis AL ; . Blood. 2005; 105: 2949-2951. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004; 5: 112-117. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C, Gonzalez M, San Miguel JF. The combination of thalidomide, cyclophosphamide and dexamethasone ThaCyDex ; is feasible and can be an option for relapsed refractory multiple myeloma. Hematol J. 2002; 3: 43-48. Guidelines Working Group of UK Myeloma Forum, British Commitee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004; 125: 681-700. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL primary ; amyloidosis. N Engl J Med. 2002; 346: 1786-1791. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003; 122: 78-84.
Moreau et al described prolonged survival and prolonged response in a 46-year-old patient with cardiac amyloidois and disseminated disease treated with high-dose melphalan and autologous bone marrow transplantation.
PNG Institute of Medical Research, P. O. Box 376, Madang, Papua New Guinea.
Infiltration with well-differentiated lymphocytes and atypical or lymphocytic plasma cells in biopsy samples of involved organs, a monoclonal IgM component of at least 5 g L electrophoresis study, and primary resistance or first relapse despite administration of treatment regimens based on alkylating agents. Patients were treated according to a randomized phase II protocol approved by an institutional review board and a local ethics committee. All eligible patients provided written consent to their participation in the study. Clinical and biologic characteristics of the patients are summarized in Table 1. All patients had received alkylating-agent monotherapy chlorambucil, cyclophosphamide, or melphalan ; with or without a corticosteroid. None of the patients had received purine analogs or doxorubicin. Fifty patients had first relapse 8 were receiving therapy when relapse occurred ; and 42 had primary resistant disease. Patients were randomly assigned to receive fludarabine 25 mg m2 of body-surface area given intravenously during 30 minutes daily for 5 consecutive days ; or CAP 750 mg m2 cyclophosphamide and 25 mg m2 doxorubicin given intravenously on day 1, and 40 mg m2 prednisone given orally on days 1-5 ; . Treatment courses were repeated every 4 weeks, with a target of 6 courses. Oral trimethoprim-sulfamethoxazole 200 mg day and 40 mg day ; or pentamidine aerosols 300 mg once a month ; and oral acyclovir 800 mg day ; were given to patients treated with fludarabine to prevent Pneumocystis carinii and herpesvirus infection, respectively, during all courses of chemotherapy. Evaluation of responses Tumor burden was assessed by means of computed tomographic assessment of the chest, abdomen, and pelvis, with measurement of all involved lymph nodes, the liver, and the spleen. The pretreatment assessment included complete blood cell counts, kidney and liver function tests, serum and urine protein electrophoresis and immunoelectrophoresis, and assays of serum immunoglobulin, lactate dehydrogenase, 2 microglobulin, and C-reactive protein. Bone marrow aspirates or bone marrow trephine biopsy samples were obtained to determine the percentage of lymphocytes, lymphocytoid plasma cells, and plasma cells. The response criteria were adapted from those used for multiple myeloma and from previous studies of WM. A partial response was defined as a sustained decrease of more than 50% in the IgM production rate on densitometry tracing of the serum electrophoretic pattern ; on at least 2 occasions 2 months apart and a more than 50% reduction in the size of all involved organs. A complete response was defined as disappearance of the monoclonal IgM on immunofixation study ; , resolution of lymphadenopathy and splenomegaly, and a finding of less than 20% lymphocytes in the bone marrow. Patients with a response were subsequently monitored without treatment until disease progression, defined as a more than 25% increase in tumor mass relative to the lowest level achieved. Treatment was considered to have failed in patients with a mixed response, no response, or withdrawal from the trial for any reason. Assessment of adverse effects All patients were included in the evaluation of adverse effects, and toxicity was analyzed according to World Health Organization criteria. Hematologic and memantine.
Melphalan order
Low doses of oral melphalan have a similar response rate to low-dose cytarabine in small trials; however, the long-term consequences of ongoing alkylator therapy in this patient population are unknown and potentially harmful.
The studies reported here demonstrate a significant correlation between the sensitivity in vitro of LCFU-c to ara-C and DNR and the ability of a remission induction regimen composed of these drugs to induce a complete hematologic remission. When considered alone, the killing of LCFU-c by DNR was more highly correlated of ara-C with treatment on LCFU-c, outcome than perhaps reflecting was the effect the relative and meperidine.
Randomization included ifosfamide in combination with etoposide VIE ; . No difference was identified between the higher-dose VAC and the ifosfamidecontaining schedules, and VAC remains the combination of choice for future IRSG now COG ; studies. The rationale for this is explained by the lesser cost and easier shorter ; duration of administration required for cyclophosphamide, and concern about the nephrotoxicity of ifosfamide. Nevertheless, the EpSSG has chosen to retain ifosfamide as their standard combination as the experience of significant renal toxicity at cumulative ifosfamide doses less than 60 g m2 now very small and there are preliminary data suggesting that the gonadal toxicity of ifosfamide may be significantly less than that of cyclophosphamide. Experience of the value of other drugs in IRSG studies has been relatively slim. IRS-III included the addition of cisplatin and etoposide in a three-way randomization between VAC, VAC with doxorubicin and cisplatin, and VAC with doxorubicin, cisplatin and etoposide. No advantage was seen in selected Group III and all Group IV patients and there were concerns about additive toxicity. IRS-IV and an earlier IRS-IV pilot ; explored the value of melphalan in patients with metastatic RMS or undifferentiated sarcoma. Patients were randomized to receive three courses of vincristine and melphalan VM ; or four of ifosfamide and etoposide IE ; Study 9 ; . There was no significant difference in initial CR and PR complete and partial remission, respectively ; rates. However patients receiving VM had a lower 3-year event-free and overall survival. Patients receiving this combination had greater hematological toxicity and therefore a lower tolerance of subsequent therapy. Other agents that have shown activity in RMS include irinotecan CPT11 ; which in combination with vincristine in a recent COG window study had excellent PR and CR rates. The current COG IRS-V study has now included this combination in their latest randomized study. Vinorelbine is well tolerated and has been evaluated in combination with daily oral cyclophosphamide in previously heavily treated patients with relapsed RMS with encouraging results. This combination is now under investigation in the current EpSSG study in which patients who achieve CR with conventional chemotherapy and local treatment are randomized to stop therapy or to continue to receive a further 6 months "maintenance" therapy with this combination.
The interpreter's statement must be completed only if the member does not understand the language on the consent form or the language used by the person obtaining consent and needs an interpreter. If this section is used, the interpreter must sign and date the consent form, using the date informed consent was given. The physician must fully complete the "Physician's Statement" section. The "Date of Surgery" must list the specific date; "to be scheduled" and "after delivery" is not acceptable. The "Date of Physician's Signature" must occur within one day of the date of surgery and mephenytoin.
I currently the 1st supervisor for the following PhD students listed with current year of study and thesis topic ; : 1. Adam Barker 3rd year ; Distributed multi-agent protocols in support of grid experimentation. 2. Paolo Besana 2nd year ; Dynamic ontology mapping for multi-agent systems. 3. Ana Costa e Silva 1st year ; Task-specific ontology mapping in distributed environments. 4. Fadzil Hassan 3rd year ; Managing finite domain constraints in multi-agent interactions. 5. David Lambert 3rd year ; Uncertainty in semantic web service provision. 6. Guo Li 3rd year ; Enacting business process requirements models via distributed multi-agent protocols. 7. Siu-wai Leung 5th year part time ; Automated synthesis in support of internet based experimentation. 8. Paul Martin 1st year ; Social group formation in multi-agent systems. 9. Nardine Osman 2nd year ; Model checking for multi-agent coordination. 10. Maciej Zurawski 3rd year ; A formal framework for multi-context knowledge management.
Tients with neutropenia, 10% with thrombocytopenia, 9% with deep vein thrombosis, 4% with somnoMP MD Dex Dex + IFN lence, and 2% each with tremor and n 109 ; n 110 ; n 109 ; n 101 ; ataxia.30 Responses again were very Quality of initial response rapid, with a median time to 50% At least a partial response 41% 70% 40% Complete response 1% 3% 1% disease reduction of 2 months, and 72% of patients achieved at least a Long-term outcome measures Median progression-free survival 21.1 mos. 22.9 mos. 12.2 mos. 15.2 mos. partial response, including 10% with Median overall survival 34.0 mos. 39.6 mos. 33.4 mos. 32.0 mos. a complete response. Median time Toxicities to disease progression was found to Deaths due to progression 1 ; 0 3 ; 21.2 months, while the median Severe pyogenic infection 12 11% ; 22 20% ; 14 13% ; 11 ; overall survival was 28.2 months. Any severe toxicity 20 18% ; 36 33% ; 34 31% ; 31 ; The encouraging results from the phase II study of MPT prompted Abbreviations: Dex, dexamethasone; IFN, interferon; MD, melphalan and dexamethasone; Palumbo et al to proceed with a ranmos., months; MP, melphalan and prednisone; n, number of patients in each cohort domized phase III trial comparing MP with MPT as initial therapy in agent thalidomide MPT ; . While this drug was first noted patients aged 60-85 years old.31 MPT was associated with a to have activity against relapsed refractory disease, 24 pre- significantly increased risk of grade 3 or 4 thromboemboclinical25 as well as clinical studies have documented its lic complications, neurologic toxicities, infectious events, ability to add to the efficacy of other agents used against and gastrointestinal problems compared to MP. As a result multiple myeloma, such as steroids, included as part of of the thromboembolic complications, low-molecularfront-line therapies.26, 27 Palumbo et al therefore enrolled 49 weight heparin prophylaxis was instituted during the trial consecutive patients, ages 61-82, with newly diagnosed in the form of enoxaparin Table 6 ; . This reduced the incimultiple myeloma, treated them with this three-drug oral dence of grade 3 or 4 events from 57% in the first 65 pacombination Table 6 ; , and evaluated responses using the tients, to 39% in the next 64 patients P 0.042 ; . Notably, stringent criteria recommended by the European Group for despite this overall increased risk of adverse events, espeBlood and Marrow Transplantation EBMT ; International cially in the first cohort of patients enrolled and treated Bone Marrow Transplant Registry.28 Toxicities that reached before enoxaparin was used, 20 patients died on the MPT a severity of grade 3 or 4 included hematologic complica- arm 16% ; compared with 27 21% ; in the MP group. Pations in 22%, thromboembolic episodes involving either tients receiving MPT had a better overall response rate than venous or arterial events in 20%, infections in 12%, in- those randomized to MP Table 7 ; , and the quality of the cluding pneumonia and herpes zoster, neurologic compli- responses was better as well, with more complete, nearcations in 8%, including paresthesias and coma, constipa- complete, and very good partial responses. Also, there was tion in 6%, and cutaneous and cardiac events, seen in 2% a lower incidence of both non-responsive disease, as well each.29 This regimen did induce an overall response rate, as progressive disease with MPT. Longer-term follow-up defined as those patients who achieved at least a partial showed that 42 of 129 patients treated with MPT suffered response, of 73%, including the 24% of patients who at- progression, relapse or death 33% ; , compared with 62 of tained either a complete response CR ; or near-CR. Re- 126 49% ; on the MP arm. This translated into a 2-year sponses were seen rapidly, with more than 50% of patients event-free survival of 54% on MPT compared with 27% on reaching a PR within the first 2 months of therapy, and a MP P 0.0006 ; . At 3 years, the OS rate was 80% for those median time to maximum response of 4 months, thus over- on MPT versus 64% for those with MP alone, providing a coming one of the disadvantages of MP with its relatively clear indication that MPT needs to be considered as a stanslow onset of action. Longer-term follow-up showed that dard of care for older patients with multiple myeloma. A randomized phase III trial comparing MP to MPT the estimates for event-free and OS at 2 years were 64% and has also been performed by the IFM, 32 and incorporated a 91%, respectively. A less dose-intensive approach to this concept was third arm with standard induction chemotherapy followed taken by Dimopoulos et al, who used MD as their back- by mobilization and intermediate-dose melphalan supbone and also added thalidomide MDT ; , but the latter was ported by stem cell rescue. The latter was included in part given for only 8 days every 5 weeks Table 6 ; in 50 pa- because of data showing that this reduced-intensity aptients who were at least 75 years of age. This intermittent proach, with melphalan at 100 mg m2 Mel 100 ; , showed a dosing schedule seemed to induce a decreased risk of some survival advantage compared to MP in myeloma patients toxicities, such as grade 3 or 4 constipation, which was not aged 50-70 years.33 In the final analysis of this three-arm seen at all with MDT, but other grade 3 or 4 events were study, MPT was associated with a higher risk of grade 3 or comparable to those seen with MPT, including 22% of pa- 4 neutropenia, infections, thrombocytopenia, thromboem and meprobamate.
Purpose Results of a prospective randomized trial conducted by the Intergroupe Francais du Myelome IFM 90 ; indicated that autologous hematopoietic cellsupported high-dose therapy HDT ; effected higher complete response rates and extended progression-free survial PFS ; and overall survival OS ; compared with standard-dose therapies SDT ; for patients with multiple myeloma MM ; . Patients and Methods In 1993, three North American cooperative groups launched a prospective randomized trial S9321 ; comparing HDT melphalan [MEL] 140 mg m2 plus total-body irradiation 12 Gy ; with SDT using the vincristine, carmustine, MEL, cyclophosphamide, and prednisone regimen. Responders on both arms 75% ; were randomly assigned to interferon IFN ; or no maintenance treatment. Results With a median follow-up time of 76 months, no differences were observed in response rates between the two study arms HDT, n 261 patients; SDT, n 255 patients ; . Similarly, PFS and OS durations did not differ between the HDT and SDT arms, with 7-year estimates of PFS of 17% and 16%, respectively, and OS of 37% and 42%, respectively. Of 242 patients achieving at least 75% tumor reduction, no difference was observed in PFS or OS among the 121 patients randomly assigned to IFN and the 121 patients randomly assigned to no maintenance therapy. Among 157 patients relapsing on SDT, 87 received a salvage autotransplantation; their median survival time of 30 months was only slightly better than the survival time of the remaining patients who were managed with further SDT 23 months; P .13 ; . Conclusion The HDT and SDT regimens used in S9321 yielded comparable response rates and PFS and OS durations. IFN maintenance therapy did not benefit patients who achieved 75% tumor reduction on either arm. J Clin Oncol 24: 929-936. 2006 by American Society of Clinical Oncology.
The questions in each quiz are drawn from the material given in that particular issue of the InteRyc under the headings of Strabismus Summary Series, Update, InformIT and Short Review article on Strabismus etc. 4. The update questionnaire is printed on the back of the CME quiz. Please answer it if there is any change or addition in the information about phone No., FAX number, mobile phone number, pager number, E-mail address or a web-site address. 5. About the election of the office bearers please refer to pp. 5-6, vol.3, 1999 ; : Only five names have been received for the post of member of the executive council and none for that of office-bearers. This number is clearly insufficient. Please come forward and volunteer so that we can hold elections. We shall have the election by postal ballot, as is the practice in some International organizations like International Strabismological Association. 6. Editorship of the soon-to-be-revived "Indian Orthoptic Journal": I happy to announce that Dr. S.K. Pal of Calcutta has agreed to take on the difficult task of executive editorship of the Indian Orthoptic Journal. Editorial board members' names will be announced soon. 7. Background of the journal: Dr. Sudha Awasthi Patney ; was inspired greatly by her teacher Mr. T. Keith Lyle read about him under the heading of "In fond memory" on the inside of back cover ; . He stressed the need of making the subject of strabismus popular among ophthalmologists and campaigning for early diagnosis in infants and children to prevent amblyopia. After coming back to Sitapur Eye Hospital in 1961, she conceived the idea of bringing out an Indian Journal of Orthoptics on the lines of the British Orthoptic Journal. Dr. J.M. Pahwa who liked the idea and agreed to look after the practical aspect ; and Dr. Awasthi Patney ; started the journal in 1963 and looked after it as the editor and the joint editor respectively until her departure from Sitapur in 1972. Dr. Pahwa continued publishing it until a few years back. About 2 years back he asked Dr. Patney if she would like to restart publishing the journal to which she replied in the affirmative. The journal would probably replace the InteRyc, as it will be difficult to publish both. Dr. Pahwa sent some old papers relating to the society sometime back for which we are grateful to him. We are going to invite him to become an honorary fellow of the society he served in the past as president for a year. 8. I.D. cards: Only six members have sent their photographs for making laminated ID cards. This is an appeal to the other members to please send their photographs so that their cards can be prepared and sent to them. We need ID card stamp size photos. However, the members who have sent passport size photos, need not send smaller ones We reduced the size on the computer. 9. The fees for the whole of theory part of fellowship course are now Rs.1500 including the mailing charges. The mode of mailing each installment is eit her by and mercaptopurine.
This decision tree is for patients with stage IIB and some stage IIIA cancers. As noted in the staging section on pages 1214, there are several combinations of T and N categories that are classified as stage IIIA. Although some stage IIIA cancers are considered in this decision tree, others are considered in Figure 4.
Background and Aims. Multiple myeloma MM ; is a neoplastic disease, that affects especially the elderly, even if in recent years it has also been observed in young patients. Painful osteolytic bone destruction is a frequent complication of MM. Bisphosphonate therapy has been shown to reduce complications of bone lesions in MM and in other malignancies. In details, it seems that zoledronate, a new generation aminobisphosphonate, also exerts antitumor effects on myeloma cells; this drug has cytotoxic activity because it causes apoptosis and block of the proliferation. Another frequent issue in patients with MM is anemia that is due both to disease progression and chemotherapy. Moreover, on the basis of the osteolytic bone lesions and anemia recorded in patients with MM, we will evaluate the percentage of regression of bone lesion after the treatment with zoledronate and the level of haemoglobin after the treatment with darbopoetin-. It is well known that myeloma cells compete with normal progenitors, and above all with erythroid precursors, for the same marrow microenvironment. We hypothesize that the stimulation of erythroid precursors in addition to the concomitant anti-proliferative effects exerted by zoledronate on myeloma cells induce an anti-tumour effects in myeloma patients. Methods. Starting from June 2004, we are following 30 patients with stage II III MM and 23 out of 30 are currently treated, independently from the adopted chemotherapy, with zoledronate 4 mg i.v. every 28 days ; because they had osteolytic bone lesions at the diagnosis. In 8 out of 23 patients we have suspended chemotherapy after 12 cycles of Melphalan and Prednisone regimen for excessive toxicity even if they presented persistent disease at cytological examination of bone marrow blood and of serum markers. In these patients, on the basis of the anemia recorded median Hb: 8.2 g dL, r. 7.8-9.2 ; , we have associated a treatment with 150 micrograms s.c. darbopoetin once a week. We have performed biological studies to evaluate the antiproliferative effect of zoledronate and darbopoetin, used alone and in combination, on myeloma cell lines. We have seeded myeloma cells in 96-multiwell plates ad after 24h incubation at 37C the cells were incubated with 3 different concentrations of the drugs. We have based drug combination studies on concentration-effect curves generated as a plot of the fraction of surviving cells versus drug concentration, after 72h of treatment. Results. At 6 months from the beginning of the treatment with zoledronate all the 30 patients treated by zoledronate had a partial or complete regression of bone lesions. In the patients treated by darbepoietin, after 6 weeks, all the 8 patients had an increase of haemoglobin median: + 1.5 g dL, r.: + 1.2-2 ; and, at a clinical re-staging performed after three months from the beginning of Zoledronate-Darbepoietin combined administration, a partial remission was recorded in 6 out of 8 patients while the remaining was in persitent disease. The data obtained from biological studies show a clear antiproliferative effect of zoledronate and darbepoetin on myeloma cell lines, effect closely releated to drug concentration. Conclusion. In our study, the combined administration of zoledronate and darbepoetin in patients affected by refrac and meropenem.
Kneisl et al. from the Carolinas Medical Center Charlotte, NC ; reported on July 27 ahead of print in Clinical Orthopaedics and Related Research on the use of 18F-FDG PET to detect occult nonpulmonary metastases in young patients newly diagnosed with either Ewing's sarcoma or osteosarcoma. The retrospective study included data from 55 patients who were younger than 30 years old at initial imaging. PET detected metastases in 12 22% ; of these patients, 8 of whom 67% ; had disease outside the lung. Only 4 7%; 3 [18% of] patients with Ewing's sarcoma and 1 [3% of] patient with osteosarcoma ; were upstaged to stage IV solely as a result of PET findings. In patients with Ewing's sarcoma, the most important alteration in treatment decision was the substitution of radiation for surgery for local control. Clinical Orthopaedics and Related Research and melphalan.
Please verify that the product information is correct and select the format s ; you require. Product Name: Web Address: Office Code: Antivirals - Global Strategic Business Report : researchandmarkets reports 362143 OCGDIOLPTVU and mesna.
Alemtuzumab is a humanized antibody that reacts with the CD52 molecule that is found on both normal and malignant B- and T-lymphocytes, as well as NK-cells, monocytes, macrophages and tissues of the male reproductive system.[14] It was approved in May 2001 based on objective responses in patients with CLL that had relapsed after treatment with fludarabine. Alemtuzumab was also evaluated in 50 patients with previously treated indolent lymphoma. Alemtuzumab, when given with rituximab, has produced a response in 10 out of 22 patients with CLL and it would be rational to use this combination in low-grade lymphomas.[15] Alemtuzumab is the foundation of many eradication-based treatment approaches because of its ability to achieve clinical remissions and to successfully purge minimal residual disease MRD ; from both blood and bone marrow in B-CLL patients. The ability to clear MRD from bone marrow in patients achieving clinical complete response CR ; using alemtuzumab is a significant step forward in the treatment of B-CLL, and supports treatment strategies combining alemtuzumab with other agents. Purging of MRD from both blood and bone marrow also enables patients for autologous hematopoietic stem cell transplantation, a strategy to achieve long-term remission.[16] Forty-one consecutive CLL patients underwent allogeneic hematopoietic cell transplantation after conditioning with fludarabine, melphalan and alemtuzumab. The alemtuzumab based regimen was feasible and effective in patients with CLL with a relatively low rate of graft versus host disease . However, transplant related mortality remains relatively high as a result of a variety of viral and fungal infections. Studies are on to test the efficacy of reduced doses of alemtuzumab in this group of highly immunosuppressed patients.[17] Gemtuzumab ozogamicin Gemtuzumab ozogamicin is a humanized MAb directed against CD33 linked to a calicheamicin derivative. This molecule is a member of the enediyne family of antitumor antibiotics, which are more cytotoxic than other clinically used.
We have in the past reported [Souliotis et al., Mutat Res 2004; 568: 155-170] that O6-methylguanine O6-meG ; was lost from the DNA of HepG2 cells over two phases with substantially different repair rates t1 2 ~ 4.7 and 26.8 h ; . The first phase was inhibited by treatment with -amanitin, an inhibitor of RNA polymerase II-mediated transcription, which also induces chromatin condensation. On the other hand, the rate of repair of O6-meG in rat tissues did not exhibit strand specificity or dependence on the transcriptional state of genes, suggesting that the abovementioned effect of amanitin reflected changes in the state of chromatin condensation rather than the inhibition of preferential repair of transcribed sequences. Recently we have observed that the nucleotide excision repair NER ; of DNA adducts induced by the nitrogen mustard melphalan shows some striking kinetic similarities with that described above for O6-meG. Using human lymphocytes, as well as human fibroblasts proficient or deficient in one or both of the global genome repair GGR ; and transcription-coupled repair TCR ; sub-pathways of NER, we have observed the following: a ; The rate of adduct repair in three active genes b-actin, p53, N-ras ; and one silent gene d-globin ; of human lymphocytes varies in the order b-actin p53 N-ras d-globin. However, no strand bias was found, indicating that this gene-specificity is not mediated by transcription-coupled repair. Micrococcal nuclease digestion showed that chromatin "looseness" varied in the order bactin p53 N-ras d-globin, suggesting that chromatin structure was the main determinant of genespecific repair efficiency. b ; Repair is multiphasic, with the early, rapid phase being inhibited by amanitin only for the three active genes. Again, this suggests that chromatin structure associated with increased transcriptional activity also favours nucleotide excision repair, as it does MGMT repair. c ; Multiphasic and gene-specific repair was observed in human fibroblasts against both TCR and GGR repair backgrounds, with differences in early repair appearing to determine the gene specificity of repair efficiency. To conclude, our results suggest that the repair efficiency of both O6-meG and melphalan adducts, although depended on different cellular mechanisms MGMT and NER, respectively ; , is profoundly affected by the local chromatin structure and mesoridazine.
In this appendix we define what it means for a monad or a category to be `suitable' and prove in outline the results on free multicategories stated in 6.5. First we need some terminology. Let E be a cartesian category, I a small pI category, D : I E functor for which a colimit exists, and D I ; E gives rise to a new functor D : I and a colimit cone. Any map L pI a new cone D I ; E pullback: if L denotes the functor I E E constant at L then D and memantine.
|
